Company Antibe Therapeutics Inc Toronto S.E.
Equities
ATE
CA0370251039
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 15-11-30 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Curtis
COO | Chief Operating Officer | - | 15-12-31 |
Joseph Stauffer
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-05-05 |
Investor Relations Contact | - | - | |
David Vaughan
PRN | Corporate Officer/Principal | 74 | 12-10-31 |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 50 | 20-11-23 | |
Amal Khouri
BRD | Director/Board Member | - | 18-03-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 53,009,362 | 48,801,128 ( 92.06 %) | 0 | 92.06 % |
Company contact information
Antibe Therapeutics, Inc.
15 Prince Arthur Avenue
M5R 1B2, Toronto
+416-922-3460
http://www.antibethera.comSector
1st Jan change | Capi. | |
---|---|---|
-1.97% | 103B | |
+7.07% | 101B | |
+4.25% | 23.07B | |
-11.71% | 22.23B | |
-4.69% | 18.05B | |
-39.98% | 17.18B | |
-11.44% | 16.94B | |
+6.13% | 14.07B | |
+36.94% | 12.35B |